



NDA 020246/S-063

SUPPLEMENT APPROVAL

Pharmacia & Upjohn Company a subsidiary of Pfizer, Inc.
Attention: Karen Baker, MS
Director, Pfizer Essential Health Global Regulatory Affairs Brands
235 East 42nd Street
New York, NY 10017-7555

Dear Ms. Baker:

Please refer to your Supplemental New Drug Application (sNDA) dated and received January 19, 2017, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Depo-Provera Contraceptive Injection (medroxyprogesterone acetate), 150 mg/ml.

This Prior Approval supplemental new drug application provides for the following:

- Editorial revisions to the font style, font size and/or font color of the proprietary name, on the carton and container labels, to improve differentiation between Depo-Provera and Depo-Medrol.
- Editorial revisions to the established name, on the carton and container labels, which include tall man lettering.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels submitted on January 19, 2017, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 020246/S-063.**” Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Meredith Alpert, MS, Safety Regulatory Project Manager, at (301) 796-1218.

Sincerely,

{See appended electronic signature page}

Christine P. Nguyen, MD
Deputy Director for Safety
Division of Bone, Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE:
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CHRISTINE P NGUYEN
03/16/2017